SCHEMBL1108634

SCHEMBL1108634

Cc1ccc(N2CC3CCC2C3)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K12 Q12852 10/20 0.44
CHRNA7 P36544 1/20 0.39
KCNH2 Q12809 1/20 0.39
PDE10A Q9Y233 1/20 0.38
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25678504 0.89 MAP3K12 (0.43) MAP3K12CHRNA7KCNH2GRIN2DGRIN3B
SCHEMBL25855693 0.81 MAP3K12 (0.50) MAP3K12CHRNA7KCNH2GRIN2DGRIN3B
SCHEMBL21861591 0.81 MAP3K12 (0.44) MAP3K12CHRNA7KCNH2PDE10AGRIN2D
SCHEMBL26151688 0.81 MAP3K12 (0.42) MAP3K12CHRNA7KCNH2
SCHEMBL25855694 0.76 MAPT (0.51) MAP3K12L3MBTL1
SCHEMBL25147712 0.75 MAP3K12 (0.50) MAP3K12
SCHEMBL15743920 0.75 MAP3K12 (0.50) MAP3K12
SCHEMBL15743901 0.75 CHRNA7 (0.66) CHRNA7KCNH2
SCHEMBL17247969 0.75 MAP3K12 (0.39) MAP3K12
SCHEMBL15743911 0.75 MAP3K12 (0.50) MAP3K12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153628-B2 Pyrazolyl substituted xanthines FOREST LABORATORIES HOLDINGS LIMITED (BM) 2012-04-10 US disclosed
US-20100273780-A1 SUBSTITUTED 8-HETEROARYL XANTHINES PGXHEALTH, LLC (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273780-A1 SUBSTITUTED 8-HETEROARYL XANTHINES ADORA2B, ADORA2A, ADORA3 MAP3K12 4111/4885CHRNA7 398/4885KCNH2 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.